{"id":15124,"date":"2021-07-09T14:05:09","date_gmt":"2021-07-09T12:05:09","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15124"},"modified":"2021-07-09T14:05:09","modified_gmt":"2021-07-09T12:05:09","slug":"acalabrutinib-en-premiere-ligne","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/acalabrutinib-en-premiere-ligne\/","title":{"rendered":"Acalabrutinib en premi\u00e8re ligne"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1240px + 0px );margin-left: calc(-0px \/ 2 );margin-right: calc(-0px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:0px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:0px;--awb-width-medium:100%;--awb-spacing-right-medium:0px;--awb-spacing-left-medium:0px;--awb-width-small:100%;--awb-spacing-right-small:0px;--awb-spacing-left-small:0px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>R\u00e9f. :HematoStat.net ; 1 (1) : V12<\/p>\n<p><a href=\"https:\/\/europepmc.org\/article\/med\/31876911\">Byrd JC, Woyach JA, Furman RR, Martin P, O&#8217;Brien S, Brown JR, Stephens DM, Barrientos J, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Acalabrutinib in Treatment-Na\u00efve Chronic Lymphocytic Leukemia. Blood. 2021 Mar 30:blood.2020009617. doi: 10.1182\/blood.2020009617. Epub ahead of print. PMID: 33786588.<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":9,"featured_media":15128,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[11],"tags":[126,127,128],"ppma_author":[451],"class_list":["post-15124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-veille-bibliographique","tag-acalabrutinib","tag-phase-1-2","tag-premiere-ligne","author-vincent-levy"],"aioseo_notices":[],"authors":[{"term_id":451,"user_id":9,"is_guest":0,"slug":"vincent-levy","display_name":"Vincent LEVY","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-13.21.23.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-13.21.23.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue, PU, PH en Pharmacie Clinique. <br>\r\nResponsable de l\u2019Unit\u00e9 de Recherche Clinique et du Centre de Recherche Clinique du GH de Seine-Saint-Denis, H\u00f4pital Avicenne. <br>\r\nMembre du CA et du CS du FILO. <br>\r\n<strong>Expertise : <\/strong>Leuc\u00e9mie lympho\u00efde chronique, essais cliniques.<br>\r\n<strong>Liens d'int\u00e9r\u00eat au 01\/01\/2023: <\/strong> Abbvie, AstraZeneca, Janssen.<br>\r\n<strong>Correspondance : <\/strong>H\u00f4pital Avicenne CRC\/URC, 125 rue de Stalingrad 96000 Bobigny."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15124"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15124\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15124"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}